Immunohistochemical (IHC) analysis results indicated that, compared to that in the adjacent non-tumour tissues, the frequency of ROCK2-positive cells was higher and the staining intensity was stronger in CCA tissues from patients who showed a poor response to Pemigatinib (Fig. 1F, G). This evidence concerns the gene ROCK2 and neoplasm.